Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) Peptide
-
- Target See all VHL products
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequence
- EDGGEESGAE ESGPEESGPE ELGAEEEMEA GRPRPVLRSV NSREPSQVIF
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of VHL antibody,
Alternative Names: VHL control peptide, VHL antibody Blocking Peptide, Anti-VHL Blocking Peptide, von Hippel-Lindau tumor suppressor Blocking Peptide, HRCA1 Blocking Peptide, RCA1 Blocking Peptide, VHL1 Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Background
- Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
- Molecular Weight
- 19 kDa
-